Rigel Pharmaceuticals (RIGL) PT Set at $6.00 by Cantor Fitzgerald
Cantor Fitzgerald set a $6.00 price objective on Rigel Pharmaceuticals (NASDAQ:RIGL) in a research note published on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other research firms have also recently weighed in on RIGL. Zacks Investment Research cut Rigel Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, March 10th. Piper Jaffray raised their price target on Rigel Pharmaceuticals from $6.00 to $7.00 and gave the company an overweight rating in a research note on Tuesday. BidaskClub upgraded Rigel Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, December 29th. ValuEngine upgraded Rigel Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, February 7th. Finally, HC Wainwright restated a buy rating and issued a $7.00 price target on shares of Rigel Pharmaceuticals in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $6.71.
Shares of NASDAQ RIGL opened at $3.84 on Tuesday. Rigel Pharmaceuticals has a 12-month low of $2.14 and a 12-month high of $4.71.
Institutional investors have recently bought and sold shares of the business. UBS Asset Management Americas Inc. acquired a new stake in Rigel Pharmaceuticals in the fourth quarter valued at $105,000. Quantitative Investment Management LLC acquired a new stake in shares of Rigel Pharmaceuticals during the fourth quarter worth about $109,000. Teacher Retirement System of Texas acquired a new stake in shares of Rigel Pharmaceuticals during the fourth quarter worth about $181,000. SG Americas Securities LLC increased its position in shares of Rigel Pharmaceuticals by 415.2% during the third quarter. SG Americas Securities LLC now owns 59,401 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 47,872 shares in the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Rigel Pharmaceuticals by 42.5% during the fourth quarter. Mackenzie Financial Corp now owns 64,062 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 19,091 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.